AGER and Alzheimer disease: The phase III 18 month clinical trial of the RAGE inhibitor TTP488 is being planned for mild to moderate AD patients (The U.S. National Institutes of Health, 2014); positive results in phase II testing have been reported (Burstein et al., 2014).